EBOS Group Limited 2026年第四季度财报及全年电话会议纪要

发布时间：2026-08-19 一、AI总结内容 一、核心要点 1. 2026财年（FY26）EBOS集团营收增长9.9%至135亿澳元， underlying EBITDA增长5%至6.14亿澳元，完成3.6亿澳元配送中心（DC）更新计划，85%EBITDA来自行业头部业务2. FY26完成8项 bolt-on 收购，未来资本支出（CapEx）将正常化至约1亿澳元，拥有约1.5亿澳元额外并购资金能力3. 2027财年（FY27）目标实现中单位数EBITDA增长，各分部优先事项明确，资本投资周期已进入新阶段 二、分部业务表现 1. 医疗保健分部营收增长8.5%至126亿澳元，EBITDA增长3.2%至5.16亿澳元，完成DC更新，GLP1类药物需求强劲2. 零售药房品牌营收增长，网络达780家，自有品牌营收增11%，数字交易增30%，CareClinic服务超1200万次3. 医疗技术分部营收增长5.5%（固定汇率8.4%），拓展18个供应合作，肿瘤、骨科等领域收购落地4. 动物保健分部营收增长34.6%至9.07亿澳元，EBITDA增长11.6%至1.38亿澳元，Kiwi Kitchen重返美国市场，SVS收购贡献增量 三、投资与财务 1. FY26分红保持每股61.5澳分，杠杆率2.1倍处于目标区间，自由现金流因CapEx下降将显著改善 2. 资本配置优先保障资产负债表、分红，同时投向高增长业务，并购注重收益性与协同性四、风险与关注点 1. 外汇、燃料价格波动及医药行业竞争、 tiering 政策调整对短期业绩存在影响2. 新西兰业务受高汇率影响EBITDA下滑， capital 销售基数波动存在短期扰动3. 配送中心利用率提升及新西兰合同续约等需持续推进，FY27需关注资本使用效率 二、音频原文（转写） Thank you for standing by and welcome to EBO's Group Limited FY 26 full year results conferencecall. At this time, all participants are in listen only mode. There will be a presentation followed by a question and answer session, at which time, if you wish to ask a question, you will need to press star one one on your telephone keypad. You can cancel your request by pressing star one one again. I must advise you that this confer ence is being. recorded today, the 19th of August 2026. I'd like to hand the call over to your first speaker today, Mr. Cameron Sinclair, head of investor relations, Evos Group. Please go ahead, Cameron. Good morning, everyone, and thank you for your attendance today. My name is Camden Sinclair, Head of Investor Relations. I'm joinedtoday by Adam Hall, our group CEO and Alistair Gray, our group CFO. Before commencing, I'd liketo draw your attention to the disclaimer on Page2 of the presentation. The results are expressed in Australian dollars, unless otherwise noted.and the presentation refers to both statutory and underlying results. The commentary this morning is predominantly based on our underlying results. And a reconciliation is included in the appendix. I'll now hand over to Adam to take you through today's presentation. Thanks Cameron. Goodmorning everyone. There are 3 messages to takeaway from today's results. first We delivered onour commitments while completing a major phaseof investment. Revenue increased 9.9%. to thirteen point five billion dollars and underlying EBITDA increased 5% to $614 million. 不好意思。 within gardens. We also completed our multiyear360 million dollar distribution center renewal program. with all facilities now in operation. second Each division has clear growth opportunities in FY 27. across Cymbian and health care distribution Retail pharmacy brands. medical technology and animal care. We have identifying issues that support continued earnings growth. each of these initiatives is underpinned by 2 common macro themes strong underlying growth in care for anaging human and pet population and EBOSS's competitive advantages of scale. and sector leadership. As we laid out at Investor Day, eighty fivepercent of our ebitda is derived from businesseswhere we are number one. or number 2 in our sector. third We are not voting. We continue to imp rove the portfolio with 2 great bolt-on acquisitions in the last 6 months. and the capacity formore. You may recall over the last few years, we've deliberately shifted the portfolio. towardshigh growth higher return businesses. In FY '26,we continue this theme. with 8 bolt-on acquisitions that improved the quality of our portfolio.Now importantly, with about 30% lower capital requirements going forward, We have greater flexibility to continue investing in these attractivegrowth opportunities. Taken together, we enterFY '27 with earnings momentum, a completed investment cycle and additional capacity to deploy capital, the theme of confidence in their abilityto continue creating value for shareholders. Letme turn to Slide 4 and our financial guidance metrics. At the start of the year, we set clear financial targets across EBITDA, capital expenditure, depreciation amortization, financing costsand leverage. and we've delivered on these as agroup and in each division. Despite fuel costs and foreign exchange headwinds during the year, we delivered against our stated guidance ranges,noting that EBITDA guidance was revised in Aprilfollowing the disruption in the Middle East. Just as importantly, we continued to make progressagainst the strategic priorities we outlined atour Investor Day. In Symbion and Healthcare Distribution, we've now completed the DistributionCenter renewal program with all facilities operational. In reach our pharmacy brands, we expanded the network with the acquisition of medi advice, with strengthened healthcare services capabilities, and continued to improve digital transactions when we were up 30 and our own brand performance. In NAEPAL technology, we broadened our therapy and product portfolio with 18 new supply partnerships, and we grew the business both organically and through targeted acquisitions. And inanimal care, we expanded inn